# China NMPA Drug Inspection - Hubei Jurui Traditional Chinese Medicine Pieces Co., Ltd. (Origin: Jiangxi) - Sea Breeze Vine

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/hubei-jurui-traditional-chinese-medicine-pieces-co-ltd-origin-jiangxi/8d16f66e-67ba-4f6a-8f22-5f137fb1c9bb/
Source feed: China

> China NMPA drug inspection for Hubei Jurui Traditional Chinese Medicine Pieces Co., Ltd. (Origin: Jiangxi) published April 02, 2018. Drug: Sea Breeze Vine. The Gansu Provincial Food and Drug Administration, on March 28, 2018, announced the findings from targeted supervision a

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Gansu Provincial Food and Drug Administration Drug Quality Announcement
- Company Name: Hubei Jurui Traditional Chinese Medicine Pieces Co., Ltd. (Origin: Jiangxi)
- Publication Date: 2018-04-02
- Drug Name: Sea Breeze Vine
- Inspection Finding: Unqualified [Identification]
- Action Taken: Relevant food and drug administration departments have taken control measures such as sealing and seizing, requiring the sampled units to suspend the sale and use of the substandard products and to rectify the situation. The provincial bureau has instructed the municipal (prefecture-level) food and drug administration departments where the sampled units are located to investigate the illegal production and sale of substandard drugs in accordance with relevant regulations, and to publicly disclose the results within three months.
- Summary: The Gansu Provincial Food and Drug Administration, on March 28, 2018, announced the findings from targeted supervision and sampling inspections conducted across the province on traditional Chinese medicine (TCM) decoction pieces. The inspections focused on products historically prone to non-compliance, adulteration, counterfeiting, or improper processing like dyeing, weight-increasing, or sulfur fumigation. As a result, 21 batches of TCM decoction pieces from various manufacturers were identified as substandard. Common violations included failures in properties, identification, content determination, and other inspection parameters such as impurities, total ash, acid-insoluble ash, and sulfur dioxide residues, indicating significant quality and purity deficiencies. The regulatory framework for these actions includes the "Drug Administration Law of the People's Republic of China" and its implementation regulations, with product evaluations based on the "Chinese Pharmacopoeia 2010" and "2015 Editions." Required actions include immediate control measures like sealing and seizing substandard products, mandates for sampled units to suspend sales, cease use, and rectify issues. Additionally, municipal food and drug administration departments must investigate and prosecute these illegal activities, publicly disclose handling results for responsible enterprises within three months, and report all relevant information to the Provincial Bureau to ensure drug quality and public safety.

Company: https://www.globalkeysolutions.net/companies/hubei-jurui-traditional-chinese-medicine-pieces-co-ltd-origin-jiangxi/1539d150-ad5c-4d9a-8f44-2f1e1caddbfc/